CIRC Announces 2023 Annual Results
HONG KONG, Apr 17, 2024 - (ACN Newswire) - China Isotope & Radiation Corporation ("CIRC" or the "Company" , together with its subsidiaries, the "Group"; Stock Code: 1763.HK) announces the audited consolidated financial statements of the Group for the year ended 31 December 2023 ("2023" or the "Reporting Period").
- HONG KONG, Apr 17, 2024 - (ACN Newswire) - China Isotope & Radiation Corporation ("CIRC" or the "Company" , together with its subsidiaries, the "Group"; Stock Code: 1763.HK) announces the audited consolidated financial statements of the Group for the year ended 31 December 2023 ("2023" or the "Reporting Period").
- For the year ended 31 December 2023, the Group operated five business segments, namely pharmaceuticals, radioactive source products, irradiation, radiation therapy equipment and related services and other businesses.
- In 2023, the Group continued to intensify our market development efforts and achieved continued growth in economic efficiency.
- As of 31 December 2023, the Group had a number of imaging diagnosis and therapeutic radiopharmaceuticals under research and development.